Physician profile
Bipin Amin
NPI 1316986458
$6,688.53
in general payments reported to CMS, 2019-2025
34 companies · $99.08 in 2025
The $99.08 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $2,363 · 2021: $393 · 2022: $196 · 2023: $1,997 · 2024: $579 · 2025: $99.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,350 · Food and Beverage: $1,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,350.00 |
| Food and Beverage | $1,325.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $2,078.83 | 2020-2022 | |
| Janssen Biotech, INC. | $1,819.32 | 2019-2025 | Imbruvica, Carvykti, Talvey |
| Novo Nordisk INC | $716.50 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $272.91 | 2019-2024 | Breztri, Airsupra |
| Lilly USA, LLC | $217.91 | 2019-2024 | Mounjaro |
| Pfizer INC. | $192.29 | 2019-2021 | |
| Seagen INC. | $154.54 | 2019-2020 | |
| Abbott Laboratories | $130.78 | 2023-2024 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $125.83 | 2019-2024 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.26 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $83.32 | 2019-2021 | |
| Amarin Pharma, INC. | $82.44 | 2019-2022 | |
| Abbvie INC. | $67.48 | 2019-2021 | |
| Exact Sciences Corporation | $62.38 | 2024 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $59.13 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.56 | 2023-2024 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $51.63 | 2022-2024 | |
| Exelixis INC. | $50.93 | 2019-2025 | Cabometyx |
| Dexcom, INC. | $32.15 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $31.55 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $30.33 | 2019 | |
| Astellas Pharma US INC | $28.18 | 2023 | Veozah |
| Allergan, INC. | $27.13 | 2019 | |
| Phathom Pharmaceuticals, INC. | $25.91 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $23.68 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.62 | 2023 | Rexulti |
| Medtronic, INC. | $21.54 | 2023 | Inpen Smart Insulin Delivery System |
| Springworks Therapeutics, INC. | $19.61 | 2025 | Gomekli |
| Lundbeck LLC | $17.73 | 2024 | Rexulti |
| Coherus Oncology, INC. | $16.64 | 2024 | |
| Genzyme Corporation | $15.23 | 2020 | |
| Clovis Oncology, INC. | $13.43 | 2021 | |
| Cequr Corporation | $12.99 | 2024 | Cequr Simplicity |
| G1 Therapeutics, INC. | $12.77 | 2023 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bipin Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.